Topic

Leslie Sandberg Orne is the president and chief executive officer of Trinity Life Sciences.

Articles

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

Strategies for Success in an Evolving Commercialization Landscape 

Meg Rivers is the former managing editor of 

Videos

Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses workforce trends in pharma and fostering an environment for psychological safety in this Pharmaceutical Executive Podcast video.

Workforce Trends in Pharma & Psychological Safety

Lisa Henderson is the former group editorial director of 

Now with a seat at the table, growing accountability, and evolving competencies, medical affairs can use its far-reaching influence to change pharma for the better.

The Nucleus of Future Pharma: Medical Affairs is a Central Cog in Enterprise Shift 

Mark Corbae is a managing director for ICR Westwicke.

The pharmaceutical industry must have crisis communications prepared now to anticipate unforeseen events—especially those that impact public trust. 

Crisis Communication Plans in Pharma

Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses ways to address the need for talent in pharma, how pharma can increase more interest in young talent, and how many roles in pharma will require a degree in the coming years in this Pharmaceutical Executive Podcast video.

Attracting Young Talent in Pharma

Corey Ford is the vice president of reimbursement and policy insights for AmerisourceBergen.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry. 

AdobeStock_527614812_Inflation Reduction Act is shown using the text and the US flag, By Andrii

What’s Next for Biopharma Under the Inflation Reduction Act

Taylor Stucky is an associate research director at CBRE, a commercial real estate services company. She specializes in research about the life sciences sector.

Artificial intelligence may find a home in clinical trials and manufacturing in the coming years, but privacy, cyber security, and determining who owns the intellectual properties could pose challenges. 

AI to Impact Clinical Trials and Manufacturing in Life Sciences 

Matthew Arnold is a principal analyst at Clarivate.

While large pharma investment in biotechs is down—as pharmas become more strategic in their selections—it is scarcely out, with the partnership dynamic between the two sides remaining strong. 

Biotech’s Survival Story: Companies Bear Down for Lean Years

Petra Jantzer, PhD, is a senior managing director and global life sciences lead at Accenture.

Selen Karaca-Griffin is a senior principal and global life sciences research lead at Accenture.

There are clear pathways that biopharma companies can take to sustain growth and remain competitive.

How Biopharma Can Accelerate Innovation and Sustain Growth

Brent Herspiegel is the CEO of Herspiegel Consulting.

Beth Schurman is the COO of Herspiegel Consulting.

When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.

Strategy